Illumina Inc. said the Chinese government has lifted a ban on the company selling its DNA sequencing machines inside the country.

Genomics company Illumina (NASDAQ:ILMN) reported Q3 CY2025 results beating Wall Street’s revenue expectations, but sales were ...

Illumina’s revenue was flat for the third quarter as the sequencing giant continues to deal with headwinds from a China sales ...

Illumina Inc (ILMN) reports robust EPS growth and strategic progress in multiomics, despite ongoing challenges in the Greater China market.

Key opportunities in the precision oncology market include the rising adoption of personalized therapies, growth in ...

Discover key Q3 2025 earnings insights for Illumina, including raised outlook, NovaSeq X growth, and margin expansion.

Having examined the options trading patterns of Illumina, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance Trading volume ...

The global next generation sequencing (NGS) market is expected to register a robust CAGR of around 15% over the next five years. This growth is primarily driven by the rising adoption of precision ...

In June 2025, the US Food and Drug Administration (FDA) issued a final guidance titled Cybersecurity in Medical Devices: ...

Illumina (($ILMN)) has held its Q3 earnings call. Read on for the main highlights of the call. Illumina’s recent earnings call painted a picture ...

Founded by former Illumina, Grail and Google leaders, Hepta is applying the technological, genomic and commercialization expertise that made liquid biopsy possible in oncology to the far larger field ...

Investing.com -- Illumina Inc (NASDAQ:ILMN) reported better-than-expected third-quarter results on Thursday, with earnings surpassing analyst estimates and the company raising its full-year outlook, ...